Sonnet biotherapeutics completes successful glp repeat dose toxicology study of il12-fhab (son-1010) in non-human primates (nhp)

The no observed adverse event level (noael) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in nhp with no evidence of cytokine release syndrome. pharmacokinetic (pk) analysis of serum samples confirmed an enhanced profile of il12-fhab over recombinant human il-12, with a half-life around 40 hours in nhp.
SONN Ratings Summary
SONN Quant Ranking